Anders Månsson
Chief Executive Officer at Anders Månsson Business Development AB
Net worth: 39 560 $ as of 2024-03-30
Anders Månsson active positions
| Companies | Position | Start | End |
|---|---|---|---|
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Chairman | 2017-05-31 | - |
RhoVac ApS
 RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Chief Executive Officer | 2019-09-01 | - |
| Anders Månsson Business Development AB | Director/Board Member | - | - |
| Chief Executive Officer | - | - | |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Chief Executive Officer | 2023-08-31 | - |
Career history of Anders Månsson
Former positions of Anders Månsson
| Companies | Position | Start | End |
|---|---|---|---|
| LIDDS AB | Chief Executive Officer | 2022-08-31 | 2023-07-31 |
| Public Communications Contact | 2022-08-31 | 2023-07-31 | |
| AMNIOTICS AB | Director/Board Member | 2021-04-14 | 2022-08-18 |
| Chief Executive Officer | 2016-12-31 | 2018-12-31 | |
| Independent Dir/Board Member | 2021-04-14 | 2022-08-18 | |
| EQL PHARMA AB | Director/Board Member | 2018-08-22 | - |
| Chairman | - | 2022-08-16 | |
| Independent Dir/Board Member | 2018-08-22 | 2022-08-16 | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | 2011-04-30 | 2017-04-30 |
| CHOSA ONCOLOGY AB | Chief Executive Officer | 2019-09-01 | - |
| Corporate Officer/Principal | 2019-03-07 | 2019-09-01 | |
| ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Anders Månsson
| University of Lund | Undergraduate Degree |
| Business School Lausanne | Masters Business Admin |
Statistics
International
| Sweden | 9 |
| Denmark | 3 |
| Switzerland | 2 |
Operational
| Chief Executive Officer | 6 |
| Director/Board Member | 4 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 10 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
 | Health Technology |
| EQL PHARMA AB | Health Technology |
| AMNIOTICS AB | Health Technology |
| LIDDS AB | Health Technology |
| Private companies | 6 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Health Technology |
| Anders Månsson Business Development AB | |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Anders Månsson
- Experience
